Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS

Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects